ClinicalTrials.gov
ClinicalTrials.gov Menu

Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01300871
Recruitment Status : Terminated (Poor patient accrual)
First Posted : February 23, 2011
Last Update Posted : September 26, 2014
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto

February 18, 2011
February 23, 2011
September 26, 2014
January 2011
Not Provided
Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ]
The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).
Severity of Alopecia Tool (SALT) [ Time Frame: At the end of the study ]
The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).
Complete list of historical versions of study NCT01300871 on ClinicalTrials.gov Archive Site
  • Comparison of Tamoxifen, AI or Tamoxifen plus AI [ Time Frame: 1 year ]
    Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.
  • Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ]
    To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT.
  • Comparison of Tamoxifen, AI or Tamoxifen plus AI [ Time Frame: At the end of the study ]
    Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.
  • Severity of Alopecia Tool (SALT) [ Time Frame: At the end of the study ]
    To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT.
Not Provided
Not Provided
 
Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Patients that attend Medical Oncology Breast Clinics at Princess Margaret Hospital.
Breast Cancer
Not Provided
Postmenopausal Women on Endocrine Therapy
Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
100
5
January 2012
Not Provided

Inclusion Criteria:

  • Postmenopausal women
  • Diagnosed with hormone-receptor positive breast cancer
  • Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole
  • Good command of the English language
  • Under the care of a medical oncologist at Princess Margaret Hospital

Exclusion Criteria:

  • Previously received chemotherapy
  • Recurrent and/or metastatic disease
  • History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)
Sexes Eligible for Study: Female
40 Years and older   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01300871
Alopecia
10-0906-CE ( Other Identifier: Research Ethics Board )
No
Not Provided
Not Provided
University Health Network, Toronto
University Health Network, Toronto
Not Provided
Principal Investigator: Lindsay Carlsson University Health Network-Princess Margaret Hospital
University Health Network, Toronto
February 2011